In May 2026, more than 50 patient and professional organisations announced a new name: Polyendocrine Metabolic Ovarian Syndrome, or PMOS (formerly PCOS) (Endocrine Society, 2026). The name changed after a long international process. The body it describes did not.
That distinction matters. A new medical term can sound as if someone has rewritten the rules overnight. This one is better understood as a clearer label for a condition clinicians and patients already know. The practical questions about records, appointments, and billing deserve their own space, so we cover those in our guide to what the rename means for your care.
What does PMOS stand for?
Polyendocrine points to the fact that more than one hormone system can be involved. Metabolic makes room for the way the condition can relate to how the body handles energy. Ovarian keeps the reproductive part of the picture visible. Together, the words describe a whole-body endocrine and metabolic condition rather than reducing it to one organ.
The longer name is not meant to make everyday conversations harder. People will keep using both terms for some time. The useful takeaway is simple: PMOS and PCOS refer to the same condition. Seeing either term on a form, an article, or an app during the transition is expected.
Why did the old name need replacing?
The older name put cysts and ovaries at the centre. That can be misleading. Ovarian cysts are not the defining feature of the condition, and they are not present for everyone (Yale Medicine, 2026).
The international group behind the change wanted a name that better matched the hormonal, metabolic, skin, reproductive, and emotional-health dimensions that may be part of the wider picture (Endocrine Society, 2026). A more accurate name cannot solve every gap in care by itself. It can, however, make it easier to start the conversation from a fuller view.
What changed, and what did not?
The change is real in language, education, research, and the way the condition is framed. It asks clinicians, researchers, and the public to look beyond the ovaries alone.
For an individual, the immediate practical picture is much steadier. The name change does not immediately alter diagnostic criteria, treatment guidance, or the terminology used in most clinical settings (Yale Medicine, 2026). If a qualified healthcare professional previously confirmed PCOS, that record still describes the same condition.
No one needs to rush to replace paperwork because of the new letters. If you want to discuss how the terminology appears in your own records or care plan, bring that question to a clinician who knows your history.
Why will I see both names for a while?
The rollout is planned as a three-year transition, with full implementation intended for the 2028 International Guideline update (Endocrine Society, 2026). Clinical guidelines, medical education, research, coding systems, and patient resources do not all change at the same speed.
That is why two names will coexist for a while. It is not a sign that one is more valid than the other. It is the normal shape of a large international terminology change.
Why Vera uses both terms
Vera uses “PMOS (formerly PCOS)” so the new language is clear without making the familiar term disappear. It is a small choice, but it helps people find information whether they search with the name they have always known or the new one they are beginning to see.
The app is a personal tracking companion, not a medical service. It reflects your logged history and treats long and variable cycles as normal for you. Day 47 is simply Day 47.
A note on medical advice
This article is general information about a terminology change. It is not medical advice and cannot tell you what the name change means for your own health or care. For questions about your records, diagnosis, or care plan, speak with a qualified healthcare professional.